Venous thrombosis: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
imported>Robert Badgett No edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
''' | {{subpages}} | ||
{{TOC|right}} | |||
A '''venous thrombosis''' is one of several diseases caused by inappropriate blood clots ([[thrombus|thrombi]]) in veins principally of the arms and legs; thromboses of the [[pulmonary vein]] or [[vena cava]] are outside the scope of this article. The major area of concern is [[deep venous thrombosis]], although there is also superficial venous thrombosis. | |||
==Deep venous thrombosis== | ==Deep venous thrombosis== | ||
{{main|Deep venous thrombosis}} | {{main|Deep venous thrombosis}} | ||
==Ovarian vein thrombosis== | |||
{| class="wikitable" border="1" | |||
|+ Comparison of risk factors amoung women with ovarian vein thrombosis and deep venous thrombosis<ref name="pmid16894453">{{cite journal| author=Wysokinska EM, Hodge D, McBane RD| title=Ovarian vein thrombosis: incidence of recurrent venous thromboembolism and survival. | journal=Thromb Haemost | year= 2006 | volume= 96 | issue= 2 | pages= 126-31 | pmid=16894453 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16894453 }} </ref> | |||
! !! Ovarian vein thrombosis!! Deep venous thrombosis | |||
|- | |||
| Increased estrogen state<br/>([[Estrogen replacement therapy|ERT]], [[Oral contraceptive|OBCP]], [[pregnancy]])|| 34% || 9% | |||
|- | |||
| Pelvic infection|| 23% || 1% | |||
|- | |||
| Abdominal surgery|| 22% || 4% | |||
|- | |||
| Underlying cancer|| 12% || 15% | |||
|- | |||
| Idiopathic|| 3% || 21% | |||
|} | |||
==Superficial venous thrombousis== | ==Superficial venous thrombousis== | ||
===Prognosis=== | ===Prognosis=== | ||
Superficial venous thrombosis can be associated with [[deep venous thrombosis]] and an accompanying deep venous thrombosis occurring simultaneously or later.<ref name="pmid20157136">{{cite journal| author=Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M et al.| title=Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. | journal=Ann Intern Med | year= 2010 | volume= 152 | issue= 4 | pages= 218-24 | pmid=20157136 | Superficial venous thrombosis can be associated with [[deep venous thrombosis]] and an accompanying deep venous thrombosis occurring simultaneously or later.<ref name="pmid20157136">{{cite journal| author=Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M et al.| title=Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. | journal=Ann Intern Med | year= 2010 | volume= 152 | issue= 4 | pages= 218-24 | pmid=20157136 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=20157136 | doi=10.1059/0003-4819-152-4-201002160-00006 }} </ref><ref name="pmid23821661">{{cite journal| author=Leizorovicz A, Becker F, Buchmüller A, Quéré I, Prandoni P, Decousus H et al.| title=Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study. | journal=Blood | year= 2013 | volume= 122 | issue= 10 | pages= 1724-9 | pmid=23821661 | doi=10.1182/blood-2013-04-498014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23821661 }} </ref> | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=20157136 | doi=10.1059/0003-4819-152-4-201002160-00006 }} </ref> | |||
===Treatment=== | ===Treatment=== | ||
"Fondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treatment of patients with acute, | "Prophylactic dose fondaparinux given for six weeks appears to be a valid therapeutic option for ST of the legs" according to a [[meta-analysis]] by the [[Cochrane Collaboration]]. <ref name="pmid22419302">{{cite journal| author=Di Nisio M, Wichers IM, Middeldorp S| title=Treatment for superficial thrombophlebitis of the leg. | journal=Cochrane Database Syst Rev | year= 2012 | volume= 3 | issue= | pages= CD004982 | pmid=22419302 | doi=10.1002/14651858.CD004982.pub4 | pmc= | url= }} </ref> | ||
"[[Fondaparinux]] at a dose of 2.5 mg once a day for 45 days was effective in the treatment of patients with acute, symptomatic superficial-vein thrombosis of the legs and did not have serious side effects" according to the CALISTO[[randomized controlled trial]]. <ref name="pmid20860504">{{cite journal| author=Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B et al.| title=Fondaparinux for the treatment of superficial-vein thrombosis in the legs. | journal=N Engl J Med | year= 2010 | volume= 363 | issue= 13 | pages= 1222-32 | pmid=20860504 | doi=10.1056/NEJMoa0912072 }} </ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Latest revision as of 08:11, 28 September 2013
A venous thrombosis is one of several diseases caused by inappropriate blood clots (thrombi) in veins principally of the arms and legs; thromboses of the pulmonary vein or vena cava are outside the scope of this article. The major area of concern is deep venous thrombosis, although there is also superficial venous thrombosis.
Deep venous thrombosis
Ovarian vein thrombosis
| Ovarian vein thrombosis | Deep venous thrombosis | |
|---|---|---|
| Increased estrogen state (ERT, OBCP, pregnancy) |
34% | 9% |
| Pelvic infection | 23% | 1% |
| Abdominal surgery | 22% | 4% |
| Underlying cancer | 12% | 15% |
| Idiopathic | 3% | 21% |
Superficial venous thrombousis
Prognosis
Superficial venous thrombosis can be associated with deep venous thrombosis and an accompanying deep venous thrombosis occurring simultaneously or later.[2][3]
Treatment
"Prophylactic dose fondaparinux given for six weeks appears to be a valid therapeutic option for ST of the legs" according to a meta-analysis by the Cochrane Collaboration. [4]
"Fondaparinux at a dose of 2.5 mg once a day for 45 days was effective in the treatment of patients with acute, symptomatic superficial-vein thrombosis of the legs and did not have serious side effects" according to the CALISTOrandomized controlled trial. [5]
References
- ↑ Wysokinska EM, Hodge D, McBane RD (2006). "Ovarian vein thrombosis: incidence of recurrent venous thromboembolism and survival.". Thromb Haemost 96 (2): 126-31. PMID 16894453. [e]
- ↑ Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M et al. (2010). "Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study.". Ann Intern Med 152 (4): 218-24. DOI:10.1059/0003-4819-152-4-201002160-00006. PMID 20157136. Research Blogging.
- ↑ Leizorovicz A, Becker F, Buchmüller A, Quéré I, Prandoni P, Decousus H et al. (2013). "Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study.". Blood 122 (10): 1724-9. DOI:10.1182/blood-2013-04-498014. PMID 23821661. Research Blogging.
- ↑ Di Nisio M, Wichers IM, Middeldorp S (2012). "Treatment for superficial thrombophlebitis of the leg.". Cochrane Database Syst Rev 3: CD004982. DOI:10.1002/14651858.CD004982.pub4. PMID 22419302. Research Blogging.
- ↑ Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B et al. (2010). "Fondaparinux for the treatment of superficial-vein thrombosis in the legs.". N Engl J Med 363 (13): 1222-32. DOI:10.1056/NEJMoa0912072. PMID 20860504. Research Blogging.